Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 3,440,000 shares, an increase of 431.1% from the November 30th total of 647,700 shares. Based on an average daily volume of 3,750,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 4.3% of the shares of the company are short sold.

Chimerix Trading Down 3.6 %

NASDAQ CMRX traded down $0.12 during trading hours on Thursday, hitting $3.22. 777,337 shares of the company’s stock traded hands, compared to its average volume of 1,266,239. Chimerix has a 52 week low of $0.75 and a 52 week high of $3.39. The firm has a market capitalization of $289.59 million, a P/E ratio of -3.43 and a beta of 1.02. The business’s fifty day moving average price is $1.45 and its two-hundred day moving average price is $1.09.

Wall Street Analysts Forecast Growth

CMRX has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Wednesday, December 11th. Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, December 10th.

Institutional Investors Weigh In On Chimerix

Several hedge funds and other institutional investors have recently modified their holdings of CMRX. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 138,098 shares during the period. Valeo Financial Advisors LLC lifted its position in shares of Chimerix by 566.9% in the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 69,505 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Chimerix in the second quarter worth about $137,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.